- **N2OFF shareholders approved the acquisition of SciSparc's majority-owned subsidiary, MitoCareX Bio Ltd., on September 25, 2025**, which will result in MitoCareX becoming a **wholly-owned subsidiary of N2OFF**.  **[1611746_0001213900-25-093386_ea025944701ex99-1_scisparc.htm:0]** 
- Under the agreement, N2OFF will purchase **6,622 shares of MitoCareX from SciSparc for $700,000** and exchange the remaining shares with all Sellers for N2OFF common stock, totaling **40% of N2OFF's fully diluted capital stock**.  **[1611746_0001213900-25-093386_ea025944701ex99-1_scisparc.htm:0]** 
- The Sellers are also entitled to **30% of N2OFF's financing proceeds (capped at $1.6 million) for five years** and **milestone-based issuances of up to 25% of N2OFF common stock**.  **[1611746_0001213900-25-093386_ea025944701ex99-1_scisparc.htm:0]** 
- The transaction is targeted to close in the **first half of October 2025**, subject to remaining closing conditions, and includes an **initial cash investment of $1,000,000** by N2OFF to support MitoCareX's operations for the first two years.  **[1611746_0001213900-25-093386_ea025944701ex99-1_scisparc.htm:0]**

SciSparc: N2OFF Shareholders Approve Merger with MitoCareX

- **N2OFF stockholders approved the acquisition of SciSparc's majority-owned subsidiary, MitoCareX Bio Ltd., on September 25, 2025**, clearing the path for MitoCareX to become a wholly-owned subsidiary of N2OFF.  **[1611746_da4d9771e9424c47b06d41244163c07c_0]** 
- Under the agreement, SciSparc will sell **6,622 shares of MitoCareX for $700,000**, and the sellers will collectively receive N2OFF common stock totaling **40% of N2OFF's fully diluted capital stock**.  **[1611746_da4d9771e9424c47b06d41244163c07c_0]** 
- The sellers are also entitled to **30% of N2OFF's financing proceeds (capped at $1.6 million)** for five years and potential milestone-based issuances of up to **25% of N2OFF common stock**.  **[1611746_da4d9771e9424c47b06d41244163c07c_0]** 
- N2OFF has committed to an initial **cash investment of $1,000,000** to support MitoCareX's operations for the first two years following the closing.  **[1611746_da4d9771e9424c47b06d41244163c07c_0]** 
- The transaction is aimed to close in the **first half of October 2025**, subject to the satisfaction of remaining closing conditions.  **[1611746_da4d9771e9424c47b06d41244163c07c_0]**

SciSparc: N2OFF Stockholders Approve MitoCareX Acquisition

- **SciSparc Ltd.** announced a new initiative to launch **quantum computing-enabled 3D protein modeling** to revolutionize AI drug discovery.  **[1611746_0001213900-25-091658_ea0258761-6k_scisparc.htm:0]** **[1611746_0001213900-25-091658_ea025876101ex99-1_scisparc.htm:0]** 
- This initiative aims to leverage quantum computing to achieve **unprecedented accuracy** in predicting protein structures and interactions, potentially accelerating drug discovery for neurological and rare diseases.  **[1611746_0001213900-25-091658_ea025876101ex99-1_scisparc.htm:0]** 
- The company plans to form a **dedicated research team**, collaborate with leading experts, and incorporate a **new wholly-owned Israeli subsidiary** to operate this initiative.  **[1611746_0001213900-25-091658_ea025876101ex99-1_scisparc.htm:0]** 
- Effective September 21, 2025, **Mr. Amitay Weiss was appointed President** and **Mr. Itschak Shrem was appointed Chairman of the Board**.  **[1611746_0001213900-25-091658_ea0258761-6k_scisparc.htm:0]**

SciSparc (SPRC)